Companies › Angiodynamics
1 active drug program in 1 registered trial: 1 Phase 3; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NanoKnife System Irreversible electroporation (IRE) device | – | Phase 3 | Stage III Pancreatic Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03899636 | NanoKnife System | Phase 3 | Stage III Pancreatic Cancer | Oncology | Apr 2025 |
Cash of $34m on 2026-08-31; operating cash outflow about $61m a year; runway about 7 months at that burn, to Mar 2027
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Intensity Therapeutics Can-Fite BioPharma LeonaBio RenovoRx Aura Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.